Scientific Sessions 2024  /  Mixing it Up: Pulmonary Hypertension in Patients with Both Heart and Lung Disease  /  Debate: Patients with Group 2 and Group 3 PH should be treated with PAH Therapies
Logo

American Heart Association

  2
  0

Final ID:

Debate: Patients with Group 2 and Group 3 PH should be treated with PAH Therapies

  • Waxman, Aaron  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Mclaughlin, Valerie  ( U of Michigan , Ann Arbor , Michigan , United States )
    • Author Disclosures:
    Aaron Waxman: DO have relevant financial relationships ; Researcher:United Therapeutics:Active (exists now) ; Researcher:35Pharma:Active (exists now) ; Researcher:Gossamer:Active (exists now) ; Researcher:Acceleron/Merck:Active (exists now) ; Researcher:OrphAI:Active (exists now) | Valerie McLaughlin: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Mixing it Up: Pulmonary Hypertension in Patients with Both Heart and Lung Disease

Monday, 11/18/2024 , 08:00AM - 09:15AM

Cardiovascular Seminar

More abstracts on this topic:
New Models to Study Group 2 Pulmonary Hypertension: Can They Be Adapted to Study Mixed Pulmonary Hypertension?

Lai Yen-chun, Agrawal Vineet

Debate: Patients with Group 2 and 3 PH should NOT Be Treated with PAH Therapies

Vachiery Jean-luc, Maron Brad

More abstracts from these authors:
Highlights from the 7th World Symposium: A 30,000 Foot View

Humbert Marc, Simonneau Gerald, Mclaughlin Valerie

You have to be authorized to contact abstract author. Please, Login
Not Available